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The first sign that Small Molecule 
Therapeutics, Inc. (SMT, Monmouth 
Junction, New Jersey) is unique is its 
name. This drug company is going to 
search for small molecule drugs. And 
that’s it. No fancy founding 
technology to draw in the 
scientifically knowledgeable 
investors, and no catchy story to sell 
to the general public. Indeed, in an 
interview shortly before the company 
opened for business in 1997, the 
CEO and founder stated: “We have 
not decided to focus on any one 
therapeutic area or technology 
platform. Our goal is to identify 
[drugs for] unmet medical needs.” 
Language like this is endemic in 
industry press releases that aim to 
obfuscate, but few CEOs will say 
such things in real life. Prabhavathi 
Fernandes was making an exception 
that day because she really didn’t 
have anything concrete to say, at least 
in public. Fernandes had left her job 
as vice-president of biomedical 
screening at Bristol Myers Squibb 
(BMS; Princeton, New Jersey) to set 
up SMT and, as she says, “coming 
out of a major company you have to 
start from scratch.” 
The one thing she had was a 
substantial reputation. “She’s very 
energetic and very enthusiastic,” says 
Daniel Chu, vice-president of 
discovery research at KOSAN 
Biosciences, Inc. (Hayward, California), 
and a former co-worker at Abbott 
Laboratories (Abbott Park, Illinois). 
“She has the momentum and strength 
to make things happen. And she’s very 
knowledgeable as a scientist.” 
On the basis of that reputation, 
which includes the research that led 
to four approved drugs, Fernandes 
was given the money to start SMT 
Now all she needed was some 
science to go with it. 
Confidence breeds confidence 
Fernandes was born in Bangalore, 
India, and studied in India, Belgium 
and the United States. In the 
pharmaceutical industry it was 
Richard Sykes, now the CEO of 
Glaxo, who showed her that drug 
hunting was a viable option. “I 
realized that you could do good 
science within major companies,” 
she says. She oversaw antimicrobial 
screens at Abbott, then moved to 
BMS to direct a variety of screening 
efforts. 
Eventually her enthusiasm for big 
pharma began to wane. “I like big 
companies - I have grown a lot 
there - but I was there for 20 years, 
and 20 years is a long time,” she says. 
“I thought I could move things along 
faster in a small company.” 
SMT is a company founded on 
reputation alone. 
This is particularly true with screens 
for antibiotics. As more antibiotics 
have been discovered (in response to 
the growing numbers of antibiotic- 
resistant bacteria), antibiotic hunts 
have increasingly turned up the same, 
or similar molecules. At Abbott, 
Fernandes had pushed the “variation 
on a theme” line successfully, 
developing a blockbuster macrolide 
called clarithromycin in the process. 
But now the easy modifications have 
been covered, and resistant bugs are 
throwing out multiple related 
chemicals in one hit. New targets are 
needed. 
SMT has selected bacterial 
topoisomerase I as its first candidate 
target. Inhibitors of this enzyme 
should work like the extremely 
successful quinolones, which 
Fernandes worked on when she was 
at Abbott. Quinolones trap DNA in a 
cleaved state by inhibiting a late step 
in the cycle of DNA gyrase 
(topoisomerase II). SMT has used a 
proprietary functional screen with 
bacterial cells to detect antibacterial 
compounds that specifically inhibit 
topoisomerase I, and confirmed that 
they inhibit the enzyme in vitro. 
Similar screens are planned with other 
targets such as RNA polymerase. 
The next step was to find money. 
“A lot of venture capitalists knew me, 
so when I called and presented what 
we could do they were enthusiastic,” 
says Fernandes. Her presentation 
centered on one major theme: in her 
words, “We’ve done it before, and we 
can do it again.” Money arrived in July 
1997 (US$Z million) and January 1998 
(US$8 million). Rolf Menzel left BMS 
with Fernandes to become executive 
vice-president, and the laboratories 
opened in November 1997. 
Building on the old 
Although Fernandes couldn’t take 
any specific intellectual property 
away from her previous employers, 
she could still use her considerable 
knowledge of successful, and 
unsuccessful screening strategies. 
New strategies: interaction disruption 
The centerpiece of SMT’s science is 
a pair of techniques designed to 
make sense of the mountain of 
genomics data that is overwhelming 
the drug industry. Genomics can, for 
example, yield a comprehensive list 
of proteins that are over-produced in 
a diseased tissue. Turning off one or 
more or those proteins might reverse 
the disease process, but the list is no 
help in determining which of the 
many proteins might be the best 
candidate for inhibition. 
The best way to tell is to come up 
with an inhibitor for each protein. 
Traditional inhibitors block active sites 
of enzymes, but much of the cell’s 
business involves protein-protein 
interactions. These interactions 
govern the assembly of countless 
cellular machines, and inhibition of 
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them could provide a way to attack 
many disease processes. Several 
companies are generating exhaustive 
lists of protein-protein interactions, 
but what is needed is a way of 
defining which of the interactions is 
functionally important in disease. 
A technique called Functional 
Interactive Screening Technology 
(FIST) is SMT’s solution to these 
dual problems. The method begins 
with two-hybrid analysis to define a 
protein-protein interaction. (In the 
standard two-hybrid technique, a 
transcription activator is fused to one 
protein partner, and a DNA-binding 
domain is fused to another; 
interaction of the two proteins is 
detected as a transcriptional read-out 
when the DNA-binding protein 
brings the activator protein to a 
promoter.) The gene encoding one of 
the interacting proteins is then 
sheared randomly, and the fragments 
are expressed with both interacting 
proteins. A fragment that disrupts the 
interaction of the full-length proteins 
(a dominant-negative protein 
fragment) is termed a functional 
domain; this fragment can then be 
expressed in a disease tissue or cell to 
test whether disruption of the 
protein-protein interaction reverts the 
disease. If  it does, SMT starts another 
two-hybrid screen - to search for a 
small molecule that can mimic the 
disruption by the functional domain. 
The alternative to FIST is 
traditional molecular biology - 
defining the exact function of the 
protein and therefore the likelihood 
of its involvement in a disease. In 
comparison, says Fernandes, FIST 
can be seen as high-throughput. SMT 
recently completed FIST analysis for 
three major proteins in one month. 
Looking outside the cell 
Just as communication networks 
inside the cell rely largely on 
protein-protein interactions, 
communication outside the cell relies 
on membrane-bound receptors. 
Thanks to their importance and 
accessibility, membrane receptors are 
the target of up to 70% of all drugs, 
according to Fernandes. SMT has 
developed its second key technology 
- the Esc/ze&ia coli Dimer 
Detection System (EDDS) - to 
monitor the status of one subset of 
these proteins - the single 
transmembrane receptors. 
In mammalian cells, binding of 
ligand to these receptors triggers 
dimerization and activation of signal 
transduction pathways. In EDDS, 
the extracellular portion of the 
mammalian receptor is fused to the 
CadC protein of E. coli. CadC 
normally detects pH change, and 
when dimerized it acts directly as a 
transcriptional activator. The fusion 
proteins made by SMT produce this 
transcriptional readout in bacteria in 
the presence of ligands such as 
insulin and erythropoietin. 
EDDS has two main uses. The 
first is to define the ligands for 
orphan receptors. These receptors 
typically turn up in genomics efforts, 
but have no known ligand. The 
ligand can be found by fusing the 
receptor to CadC, and co-expressing 
a library of extracellular proteins in 
bacteria. In bacteria that make the 
appropriate ligand, the ligand will 
dimerize the receptor and turn on a 
reporter gene. In this screen, says 
Fernandes, 10,000 clones can easily 
be screened in one night. 
Newly discovered ligands have 
potential as protein therapeutics, but 
EDDS can also be used to screen for 
small molecule replacements for both 
new and well-known ligands. EDDS 
finds small molecules that either 
mimic or interfere with the dimerizing 
effect of a ligand like insulin. 
The big question is whether 
small molecules have enough heft to 
do the job of proteins -be it 
disrupting protein-protein 
interactions or inducing dimerization. 
Fernandes cites the recent success of 
the granulocyte-colony stimulating 
factor (G-CSF) mimetic made by 
Ligand Pharmaceuticals, Inc. (San 
Diego, California) and Smith Kline 
Beecham, and believes that similar 
molecules are on the way. One key, 
she says, is ignoring the structure of 
the original ligand. “If we stop 
looking for a structural mimetic and 
start looking for a functional 
mimetic, we believe we will be 
successful,” she says. 
A family-based business strategy 
Producing drugs involves much more 
than clever assays. SMT’s approach, 
says Fernandes, is to “be the drug- 
discovery arm for companies with 
clinical and marketing prowess.” 
Other partners will provide genomics 
data, and add to the in-house 
chemistry. 
“We would like to keep it small,” 
says Fernandes. “Flexibility is a very 
big issue -we need to move fast. 
We prefer to do a lot by partnering. 
We keep our burn-rate low and get 
the job done.” 
Partnering also yields choice. “In a 
large company you have one CNS 
group, one anti-infective group, but if 
you are a small company you can shop 
the project around to the best possible 
partner,” says Fernandes. SMT hopes 
to finalize deals soon. “We did think 
people might fund us for ideas, but 
those times have come and gone - 
people want data,” says Fernandes. 
“We are working hard to get data.” 
The small size of the company - 
32 at present, and estimated to 
double eventually - has its pluses 
and minuses. “We are still very much 
part of a family,” says Fernandes, and 
decisions are made by those who 
really know about the work. But with 
a new company comes responsibility. 
“Normally you worry about yourself 
and your family,” says Fernandes. 
When you start something like this 
you want to be successful for 31 
other people. You really acquire a 
large family.” 
Not that Fernandes seems too 
worried. “Security comes from 
within,” she says. “In a big company, 
no one cares if you succeed. Here, 
why would you want to fail when 
everyone is watching?” 
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